Challenge
A leading UK University was developing a ‘3-in-1’ PCR-based assay for rapid cell line verification and purity testing. The technology comprised a PCR-based assay containing novel markers for rapid, cost-effective human cell identification and validation, including STR genotyping and rodent/mycoplasma contamination testing. The University was keen to progress with commercial engagement with a view to concluding a licensing agreement and required evidence-based guidance on the strategy and the next steps to achieving these goals, specifically including the following:
- Develop the value proposition for the technology and turn it into a pitch document to be used with prospective licensees/collaborators
- Develop a licensing strategy/plan including a plan for commercial engagement
- Provide support to licensing negotiations.
Solution
Alacrita's consultants met with the Principal Investigator and proceeded to develop a licensing strategy & plan, including:
- Establishing the development status of the technology and reviewing commercialization efforts to date
- Confirming technology value proposition in key market applications and commercial exploitation model
- Developing non-confidential and confidential pitch documents
- Compiling a database of prospective licensees
- Developing a licensing strategy & plan
The pitch documents were successfully used to engage potential collaborators and interest was generated for partnership.